IP Library › Granted Patent US 12,019,069
Granted Patent B2
US 12,019,069 · App. 16/888,252 · Granted Jun 25, 2024

Synthetic controls for immunohistochemistry

Inventors: Kathy Hötzel (Brisbane, CA); Franklin V. Peale, Jr. (Hillsborough, CA); Charles Havnar (Pacifica, CA); Linda Rangell (Pacifica, CA); Debra Y. Dunlap (Redwood City, CA)
Assignee: GENENTECH, INC.
G01N33/543G01N1/30G01N1/36G01N2333/765G01N2496/25
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,019,069
App. No.
16/888,252
Granted
Jun 25, 2024
Kind
B2
Abstract

Provided herein are methods for generating a solid antigen/carrier protein gel for immunohistochemistry (IHC) staining, as well as gels, kits and methods of use thereto. In particular, the methods, gels and kits provided herein include a purified antigen such as a polypeptide antigen, and a carrier protein such as a serum albumin protein, an egg white protein or mixture of egg white proteins, gelatin, or poly-lysine. Examples are provided in which the purified antigen is cross-linked to the carrier protein in the solid antigen/carrier protein gel.

Claims (25)

1. A method for generating a solid antigen/carrier protein gel for immunohistochemical (IHC) staining, the method comprising:

(a) mixing a purified antigen with a liquid solution comprising a carrier protein to produce an antigen/carrier protein liquid solution;

(b) cross-linking the antigen with the carrier protein using a cysteine-reactive reagent; and

(c) heating the antigen/carrier protein liquid solution to form the solid antigen/carrier protein gel,

wherein the antigen is a polypeptide antigen comprising a C-terminal cysteine,

wherein the carrier protein consists of a serum albumin protein, and

wherein the antigen/carrier protein liquid solution further comprises formaldehyde.

2. The method of claim 1 , further comprising, after (b): dehydrating the solid antigen/carrier protein gel and embedding the dehydrated solid antigen/carrier protein gel in a paraffin block.

3. The method of claim 1 , further comprising, after (b): incubating the solid antigen/carrier protein gel in a liquid embedding medium and freezing the solid antigen/carrier protein gel in the embedding medium.

4. The method of claim 1 , further comprising, after (b): embedding the solid antigen/carrier protein gel in a plastic resin.

5. The method of claim 1 , wherein the antigen/carrier protein liquid solution comprises formaldehyde at a final concentration of at least about 1%.

6. The method of claim 1 , further comprising:

after (b), dehydrating the solid antigen/carrier protein gel;

embedding the dehydrated solid antigen/carrier protein gel in a paraffin block;

sectioning the paraffin block with the embedded antigen/carrier protein gel into one or more sections having a thickness of between about 30 nm and about 50 μm;

subjecting the one or more sections of the embedded solid antigen/carrier protein gel to antigen retrieval; and

after antigen retrieval, blocking the one or more sections of the embedded solid antigen/carrier protein gel.

7. The method of claim 1 , further comprising:

after (b), incubating the solid antigen/carrier protein gel in a liquid embedding medium;

freezing the solid antigen/carrier protein gel in the embedding medium;

sectioning the frozen antigen/carrier protein gel into one or more sections having a thickness of between about 30 nm and about 50 μm; and

blocking the one or more sections of the frozen antigen/carrier protein gel.

8. The method of claim 1 , wherein the antigen further comprises an N-terminal tyrosine.

9. The method of claim 1 , wherein the serum albumin protein is bovine serum albumin.

10. The method of claim 1 , wherein the antigen/carrier protein liquid solution produced in (a) comprises the carrier protein at a concentration of greater than or equal to 2% (w/v) and less than or equal to 25% (w/v).

Continuity (4)
Continuation PCTUS2018064012 · Dec 5, 2018
Provisional Application 62730422 · Sep 12, 2018
Provisional Application 62595434 · Dec 6, 2017
Related Publication 20200292536A1 · Sep 17, 2020